CytoMed Therapeutics (GDTC) Assets (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Assets for 5 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • Quarterly Assets fell 18.6% to $6.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.2 million through Dec 2025, down 18.6% year-over-year, with the annual reading at $6.2 million for FY2025, 15.74% down from the prior year.
  • Assets hit $6.2 million in Q4 2025 for CytoMed Therapeutics, down from $7.6 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $9.2 million in Q4 2023 to a low of $3.8 million in Q4 2022.
  • Historically, Assets has averaged $6.2 million across 5 years, with a median of $6.2 million in 2025.
  • Biggest five-year swings in Assets: surged 143.24% in 2023 and later fell 18.6% in 2025.
  • Year by year, Assets stood at $4.5 million in 2021, then dropped by 15.97% to $3.8 million in 2022, then skyrocketed by 143.24% to $9.2 million in 2023, then dropped by 17.39% to $7.6 million in 2024, then dropped by 18.6% to $6.2 million in 2025.
  • Business Quant data shows Assets for GDTC at $6.2 million in Q4 2025, $7.6 million in Q4 2024, and $9.2 million in Q4 2023.